Immunotherapy is an emerging treatment which boosts a person’s own immune system to fight diseases such as cancer. There are three different classes of cancer immunotherapy including monoclonal antibodies/checkpoint inhibitors (e.g., anti-PD1), cell-based therapies (e.g., T cells), and cancer vaccines. With advances in biotechnology and better understanding of immuno-oncology, engineered T cells (e.g., CAR T cells) and nanoscale extracellular vesicles (EVs) are often used in cell-based immunotherapies and for personalized medicine. Microfluidics and nanofluidics platforms uniquely offer advantages as novel tools for cell/EV engineering, single cell manipulation and analysis, as well as study of tumor microenvironment. This special issue features articles/reviews on microfluidic-enabled technologies for immunotherapy, immunoengineering, and biomanufacturing of therapeutic cells and EVs.
Han Wei Hou, Nanyang Technological University
Aram Chung, Korea University
Chwee Teck Lim, National University of Singapore
How to Submit:
- Authors should log into PXP to submit a manuscript
- Under manuscript information → Manuscript classification → select “Microfluidics and Nanofluidics for Immunotherapy”
- Under manuscript information → Title/Abstract → select “Invited Submission: Yes” only for authors who have received a personal invitation from the Guest Editors